<unk>  (also termed<unk> <unk>  disorders and<unk> <unk>  proliferative diseases) are a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant<unk> <unk> s (sometimes in association with lymphoplasmacytoid<unk> s or B lymphocytes) over-produce and secrete into the blood stream a myeloma protein, i.e. an abnormal monoclonal antibody or portion thereof. The exception to this rule is the disorder termed non-secretory multiple myeloma; this disorder is a form of<unk> in which no myeloma protein is detected in serum or urine (at least as determined by conventional laboratory methods) of individuals who have clear evidence of an increase in clonal bone marrow<unk> <unk> s and/or evidence of clonal<unk> <unk> -mediated tissue injury (e.g.<unk> cytoma tumors). Here, a clone of<unk> <unk> s refers to group of<unk> <unk> s that are abnormal in that they have an identical genetic identity and therefore are descendants of a single genetically distinct ancestor<unk> . At one end of this spectrum of hematological disorders, detection of one of these myeloma proteins in an individual's blood or urine is due to a common and clinically silent disorder termed MGUS, i.e. monoclonal gammopathy of undetermined significance. At the other end of this spectrum, detection of the myeloid protein is due to a hematological malignancy, i.e. multiple myeloma, Waldenström macroglobulinemia, or other B<unk> -associated neoplasm, that has developed, often in a stepwise manner, from their MGUS precursors. The clinical importance of understanding this spectrum of diseases is that it can be used to: a) advise individuals on the likelihood of their condition progressing to a malignant phase; b) monitor individuals for the many complications that may occur at any stage of the<unk>  so that they can be treated to avoid or reduce their clinical impacts; and c) monitor patients for transitions to malignancy so that the malignancy can be treated at an early stage when treatment results are best. Unless otherwise noted, the advice and monitoring given here are those recommended by the International Myeloma Working Group in 2014 and updated in 2016.
Plasma cell dyscrasias
Osteopoikilosis
Sarcosinemia
Osteolysis
Osteodystrophy
Cutaneous lymphoid hyperplasia
Cysts of the jaws
Dentin dysplasia